Baird served as co-manager on this offering
AboutGenocea Biosciences Inc. (“Genocea” or the “Company”) (NASDAQ:GNCA) recently completed an underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $3.50 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,575,000 shares of common stock. The gross proceeds from the offering were $42.3 million before deducting underwriting discounts and commissions and offering expenses payable by Genocea. Genocea intends to use the net proceeds from this offering to conduct additional clinical trials evaluating the efficacy of GEN-009, to further development of GEN-011 and GEN-010 and to further invest in ATLAS™ and related research programs.
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Genocea’s unique ATLAS™ technology platform allows the Company to identify immunotherapy targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS™, Genocea can both optimize neoantigens for inclusion in the Company’s immunotherapies and exclude so-called “inhibitory” antigens that appear to exert an immunosuppressive effect on the patient. Genocea is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
- June 2019
- Genocea Biosciences Inc.
- Target Location
- North America